Early-stage drug development firm Morvus Technology has taken up a lease on a 14,000 sq ft purpose-built Science Centre at the National Botanical Garden of Wales, Carmarthenshire, to house its new headquarters.
Morvus was formed April 2004 and is involved in the discovery and development of new drugs, particularly for the treatment of cancer, up to the point of clinical trials, after which they are out-licensed.
The company's decision to locate its administration and research centre in Wales has been supported by the Welsh Assembly Government through Regional Selective Assistance and its International Business Wales bioscience team.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze